|
EP1684073A3
(de)
*
|
1997-10-21 |
2007-09-26 |
The Regents of the University of California |
Zielsequenzen für synthetische Moleküle und Verfahren zu ihrer Anwendung
|
|
US6436392B1
(en)
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
|
US6306663B1
(en)
|
1999-02-12 |
2001-10-23 |
Proteinex, Inc. |
Controlling protein levels in eucaryotic organisms
|
|
JP4969002B2
(ja)
|
1999-06-08 |
2012-07-04 |
ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン |
rAAV形質導入を増加するための化合物および方法
|
|
US7122335B1
(en)
|
1999-06-08 |
2006-10-17 |
University Of Iowa Research Foundation |
Compounds and methods to enhance rAAV transduction
|
|
US6740495B1
(en)
*
|
2000-04-03 |
2004-05-25 |
Rigel Pharmaceuticals, Inc. |
Ubiquitin ligase assay
|
|
US6979551B2
(en)
*
|
2000-04-03 |
2005-12-27 |
Rigel Pharmaceuticals, Inc. |
Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
|
|
AU2001295041A1
(en)
|
2000-09-08 |
2002-03-22 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US7208157B2
(en)
*
|
2000-09-08 |
2007-04-24 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US8241622B2
(en)
|
2001-07-13 |
2012-08-14 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
|
|
US20030077279A1
(en)
*
|
2001-10-24 |
2003-04-24 |
Cedars-Sinai Medical Center |
Methods for treating vascular disease by inhibiting toll-like receptor-4
|
|
AU2002336866B8
(en)
*
|
2001-11-01 |
2009-04-23 |
The University Of British Columbia |
Diagnosis and treatment of infectious diseases through indel-differentiated proteins
|
|
US20030148986A1
(en)
*
|
2001-12-17 |
2003-08-07 |
Cedars-Sinai Medical Center |
Methods for treating vascular disease by inhibiting myeloid differentiation factor 88
|
|
WO2004089423A2
(en)
|
2003-03-31 |
2004-10-21 |
University Of Iowa Research Foundation |
Pharmico-gene theraphy of epithelial sodium channel associated disoders
|
|
US20060183889A1
(en)
*
|
2005-01-04 |
2006-08-17 |
Bogoev Roumen A |
Alkyl phosphine detergent products and extraction processes
|
|
US9512196B2
(en)
|
2008-09-22 |
2016-12-06 |
Cedars-Sinai Medical Center |
Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
|
|
JP4879314B2
(ja)
*
|
2009-12-07 |
2012-02-22 |
独立行政法人農業生物資源研究所 |
ユビキチン依存型タンパク質分解系を利用した生体内タンパク質分解システム,及びそのシステムを利用したタンパク質の機能解明方法
|
|
BR112012023671A2
(pt)
*
|
2010-03-19 |
2017-10-03 |
Stanford Res Inst Int |
Agentes fluorescentes arsênicos e ensaios
|
|
US20120046225A1
(en)
|
2010-07-19 |
2012-02-23 |
The Regents Of The University Of Colorado, A Body Corporate |
Stable glucagon formulations for the treatment of hypoglycemia
|
|
WO2012056603A1
(ja)
*
|
2010-10-25 |
2012-05-03 |
パナソニック株式会社 |
キメラ嗅覚受容体を用いてcAMPを産生する方法
|
|
KR102438072B1
(ko)
|
2012-01-12 |
2022-08-31 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
KR101616603B1
(ko)
*
|
2012-10-11 |
2016-04-28 |
서울대학교산학협력단 |
메틸 데그론 펩타이드 및 이를 이용한 단백질 수명 조절 방법
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
JP6815318B2
(ja)
|
2014-12-23 |
2021-01-20 |
ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド |
二官能性分子によって標的化タンパク質分解を誘導する方法
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
AU2016232705C1
(en)
|
2015-03-18 |
2021-06-17 |
Arvinas, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
EP3319944A4
(de)
|
2015-07-10 |
2019-04-24 |
Arvinas, Inc. |
Mdm2-basierte modulatoren der proteolyse und zugehörige verwendungsverfahren
|
|
CA2994969A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
EP3337476A4
(de)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Verbindungen und verfahren für den gezielten abbau von bromdomänenhaltigen proteinen
|
|
BR112018008918A8
(pt)
|
2015-11-02 |
2019-02-26 |
Univ Yale |
compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
|
|
WO2017139381A1
(en)
|
2016-02-08 |
2017-08-17 |
University Of Iowa Research Foundation |
Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
|
|
WO2017155973A1
(en)
|
2016-03-07 |
2017-09-14 |
University Of Iowa Research Foundation |
Aav-mediated expression using a synthetic promoter and enhancer
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
WO2017185036A1
(en)
|
2016-04-22 |
2017-10-26 |
Dana Farber Cancer Institute, Inc. |
Bifunctional molecules for degradation of egfr and methods of use
|
|
CN121974842A
(zh)
|
2016-05-10 |
2026-05-05 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
CN109562113A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的螺环降解决定子体
|
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
|
US12173305B2
(en)
|
2016-05-26 |
2024-12-24 |
University Of Iowa Research Foundation |
cis and trans requirements for terminal resolution of human bocavirus 1
|
|
GB201610156D0
(en)
|
2016-06-10 |
2016-07-27 |
Otsuka Pharma Co Ltd |
Cliptac compositions
|
|
US11471462B2
(en)
|
2016-06-27 |
2022-10-18 |
The Broad Institute, Inc. |
Compositions and methods for detecting and treating diabetes
|
|
EP3512842B1
(de)
|
2016-09-15 |
2024-01-17 |
Arvinas, Inc. |
Indolderivate als abbauer des östrogenrezeptors
|
|
WO2018064589A1
(en)
|
2016-09-29 |
2018-04-05 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation using a mutant e3 ubiquitin ligase
|
|
SI3526202T1
(sl)
|
2016-10-11 |
2025-04-30 |
Arvinas Operations, Inc. |
Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
|
|
MX2019005007A
(es)
|
2016-11-01 |
2019-07-18 |
Arvinas Inc |
Protac dirigidos a la proteína tau y métodos asociados de uso.
|
|
IL266842B
(en)
|
2016-12-01 |
2022-09-01 |
Arvinas Operations Inc |
History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
IL325835A
(en)
|
2016-12-23 |
2026-03-01 |
Univ Yale |
Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
CN110753693A
(zh)
|
2016-12-23 |
2020-02-04 |
阿尔维纳斯运营股份有限公司 |
Egfr蛋白水解靶向嵌合分子和相关使用方法
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
US11142775B2
(en)
|
2017-01-13 |
2021-10-12 |
University Of Iowa Research Foundation |
Bocaparvovirus small noncoding RNA and uses thereof
|
|
IL300417A
(en)
|
2017-01-26 |
2023-04-01 |
Arvinas Operations Inc |
Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
|
|
IL319363A
(en)
|
2017-01-31 |
2025-05-01 |
Arvinas Operations Inc |
Cervalon ligands and bifunctional compounds containing them
|
|
EP4119552A1
(de)
|
2017-02-08 |
2023-01-18 |
Dana-Farber Cancer Institute, Inc. |
Regulierung von chimären antigenrezeptoren
|
|
EP4717317A3
(de)
|
2017-06-20 |
2026-06-03 |
C4 Therapeutics, Inc. |
N/o-verknüpfte degrone und degronimere zum proteinabbau
|
|
WO2019043217A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROBENZIMIDAZOLONES
|
|
WO2019043208A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROQUINOLINONES
|
|
CN118108706A
(zh)
|
2017-09-04 |
2024-05-31 |
C4医药公司 |
戊二酰亚胺
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
EP3710002A4
(de)
|
2017-11-16 |
2021-07-07 |
C4 Therapeutics, Inc. |
Degrader und degrone für gezielten proteinabbau
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3737666A4
(de)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Proteinabbaumittel und verwendungen davon
|
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
JP2021512153A
(ja)
|
2018-01-26 |
2021-05-13 |
イエール ユニバーシティ |
タンパク質分解のイミド系モジュレーターおよび使用方法
|
|
CN111902141A
(zh)
|
2018-03-26 |
2020-11-06 |
C4医药公司 |
用于ikaros降解的羟脑苷脂结合剂
|
|
US12539292B2
(en)
|
2018-04-01 |
2026-02-03 |
Arvinas Operations, Inc. |
BRM targeting compounds and associated methods of use
|
|
BR112020020307A2
(pt)
|
2018-04-04 |
2021-01-12 |
Arvinas Operations, Inc. |
Moduladores de proteólise e métodos de uso associados
|
|
WO2019204354A1
(en)
|
2018-04-16 |
2019-10-24 |
C4 Therapeutics, Inc. |
Spirocyclic compounds
|
|
EP3578561A1
(de)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiroverbindungen
|
|
US12454520B2
(en)
|
2018-07-06 |
2025-10-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
CN112512544B
(zh)
|
2018-07-19 |
2025-09-09 |
华盛顿大学 |
蛋白质开关的全新设计
|
|
US11707452B2
(en)
|
2018-08-20 |
2023-07-25 |
Arvinas Operations, Inc. |
Modulators of alpha-synuclein proteolysis and associated methods of use
|
|
US11969472B2
(en)
|
2018-08-22 |
2024-04-30 |
Cullgen (Shanghai), Inc. |
Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
|
|
MX2021001957A
(es)
|
2018-08-22 |
2021-07-15 |
Cullgen Shanghai Inc |
Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
|
|
AU2019389174A1
(en)
|
2018-11-30 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
JP2022520148A
(ja)
*
|
2018-12-06 |
2022-03-29 |
アークトゥラス・セラピューティクス・インコーポレイテッド |
修飾タンパク質および関連の処置方法
|
|
EP3897631A4
(de)
|
2018-12-20 |
2022-11-23 |
C4 Therapeutics, Inc. |
Gezielter proteinabbau
|
|
US11547759B2
(en)
|
2019-01-30 |
2023-01-10 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
WO2020160295A1
(en)
|
2019-01-30 |
2020-08-06 |
Montelino Therapeutics, Llc |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
ES2995214T3
(en)
|
2019-03-06 |
2025-02-07 |
C4 Therapeutics Inc |
Heterocyclic compounds for medical treatment
|
|
KR102980990B1
(ko)
|
2019-04-05 |
2026-06-25 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Stat 분해제 및 이의 용도
|
|
JP7727551B2
(ja)
*
|
2019-04-18 |
2025-08-21 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
構造的に安定化されたペプチドによるユビキチンおよびユビキチン様e1活性化酵素の選択的標的化
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
US12624044B2
(en)
|
2019-06-10 |
2026-05-12 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US12558427B2
(en)
|
2019-07-17 |
2026-02-24 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
EP3999182A1
(de)
|
2019-07-17 |
2022-05-25 |
Arvinas Operations, Inc. |
Gegen tau-protein gerichtete verbindungen und zugehörige verfahren zur verwendung
|
|
WO2021041348A1
(en)
|
2019-08-26 |
2021-03-04 |
Arvinas Operations, Inc. |
Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
MX2022004526A
(es)
|
2019-10-17 |
2022-07-21 |
Arvinas Operations Inc |
Moléculas bifuncionales que contienen una porción de unión a la ligasa de ubiquitina e3 unida a una porción de direccionamiento a bcl6.
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
EP4076524A4
(de)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
Irak-degrader und verwendungen davon
|
|
CA3161878A1
(en)
|
2019-12-17 |
2021-06-24 |
Matthew M. Weiss |
Irak degraders and uses thereof
|
|
WO2021127443A1
(en)
|
2019-12-19 |
2021-06-24 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
EP4681715A3
(de)
|
2019-12-20 |
2026-01-28 |
C4 Therapeutics, Inc. |
Isoindolinon- und indazolverbindungen zum abbau von egfr
|
|
US11679109B2
(en)
|
2019-12-23 |
2023-06-20 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
JP7815127B2
(ja)
|
2020-02-19 |
2026-02-17 |
ニューリックス セラピューティクス,インコーポレイテッド |
インターロイキン-1受容体関連キナーゼの二機能性分解剤およびその治療的使用
|
|
BR112022016901A2
(pt)
|
2020-02-26 |
2022-12-06 |
Cullgen Shanghai Inc |
Compostos de degradação do receptor de tropomiosina quinase (trk) e métodos de uso
|
|
CN119823124A
(zh)
|
2020-03-05 |
2025-04-15 |
C4医药公司 |
用于brd9的靶向降解的化合物
|
|
WO2021188948A1
(en)
|
2020-03-19 |
2021-09-23 |
Kymera Therapeutics, Inc. |
Mdm2 degraders and uses thereof
|
|
CN115996918A
(zh)
|
2020-05-09 |
2023-04-21 |
阿尔维纳斯运营股份有限公司 |
制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
|
|
EP4161521A4
(de)
|
2020-06-03 |
2024-07-10 |
Kymera Therapeutics, Inc. |
Deuterierte irak-abbauer und verwendungen davon
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
WO2021255212A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Braf degraders
|
|
AU2021319847A1
(en)
|
2020-08-03 |
2023-03-02 |
Captor Therapeutics S.A. |
Low molecular weight protein degraders and their applications
|
|
CN116490186B
(zh)
|
2020-08-05 |
2025-10-31 |
C4医药公司 |
用于ret的靶向降解的化合物
|
|
WO2022047145A1
(en)
|
2020-08-28 |
2022-03-03 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
AU2021342287A1
(en)
|
2020-09-14 |
2023-04-13 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of estrogen receptor
|
|
US12577200B2
(en)
|
2020-09-18 |
2026-03-17 |
Massachusetts Institute Of Technology |
High-throughput method to rapidly add chemical moieties to a small molecule library
|
|
TW202237095A
(zh)
|
2020-12-03 |
2022-10-01 |
德商艾斯巴赫生物有限公司 |
Alc1抑制劑及與parpi之協同性
|
|
US12606568B2
(en)
|
2020-12-09 |
2026-04-21 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
AR124547A1
(es)
|
2020-12-30 |
2023-04-05 |
Kymera Therapeutics Inc |
Degradadores de irak y sus usos
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
KR20230157443A
(ko)
*
|
2021-03-17 |
2023-11-16 |
더 트러스티즈 오브 프린스턴 유니버시티 |
펩티드 또는 폴리머에 결합된 키누레닌 및 기타 uv 흡수 산화 아미노산에서 유래된 자외선 차단제
|
|
CN118388454A
(zh)
|
2021-04-16 |
2024-07-26 |
阿尔维纳斯运营股份有限公司 |
Bcl6蛋白水解的调节剂和其相关使用方法
|
|
CA3217792A1
(en)
|
2021-05-07 |
2022-11-10 |
Kymera Therapeutics, Inc |
Cdk2 degraders and uses thereof
|
|
WO2022255888A1
(en)
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
AU2022290851A1
(en)
|
2021-06-08 |
2023-11-23 |
C4 Therapeutics, Inc. |
Therapeutics for the degradation of mutant braf
|
|
CN115704012A
(zh)
*
|
2021-08-12 |
2023-02-17 |
中国科学院深圳先进技术研究院 |
一种含有降解决定子的重组病毒及其制备方法和应用
|
|
HUE070709T2
(hu)
|
2021-08-18 |
2025-06-28 |
Nurix Therapeutics Inc |
Interleukin-1 receptorhoz kapcsolódó kinázok kétfunkciós lebontói és terápiás alkalmazásuk
|
|
EP4395549A1
(de)
|
2021-09-01 |
2024-07-10 |
Oerth Bio LLC |
Zusammensetzungen und verfahren zum gezielten abbau von proteinen in einer pflanzenzelle
|
|
US11981672B2
(en)
|
2021-09-13 |
2024-05-14 |
Montelino Therapeutics Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
WO2023066881A1
(en)
|
2021-10-18 |
2023-04-27 |
Astrazeneca Ab |
Inhibition of map3k15 for treating and preventing diabetes
|
|
JP2024540080A
(ja)
|
2021-10-29 |
2024-10-31 |
カイメラ セラピューティクス, インコーポレイテッド |
Irak4分解剤およびその合成
|
|
EP4472967A4
(de)
|
2022-01-31 |
2026-04-15 |
Kymera Therapeutics Inc |
Irak-abbauer und verwendungen davon
|
|
CN119365198A
(zh)
|
2022-05-02 |
2025-01-24 |
艾斯巴赫生物有限公司 |
ALC1抑制剂的用途和与PARPi的协同作用
|
|
IL316803A
(en)
|
2022-06-06 |
2025-01-01 |
C4 Therapeutics Inc |
Bicyclic glutarimide-modified cervalon-binding agents
|
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
EP4584258A1
(de)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Schnell beschleunigte fibrosarkom (raf)-abbauende verbindungen und zugehörige verfahren zur verwendung
|
|
JP2025540970A
(ja)
|
2022-12-06 |
2025-12-17 |
キャプター セラピューティクス エス.エー. |
ユビキチンリガーゼ及びターゲットmcl-1タンパク質に結合する二機能性化合物を使用するターゲティングされたタンパク質分解
|
|
WO2024123195A1
(en)
|
2022-12-06 |
2024-06-13 |
Captor Therapeutics S.A. |
Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
PE20260006A1
(es)
|
2023-01-26 |
2026-01-06 |
Arvinas Operations Inc |
Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
|
|
WO2024167423A1
(en)
|
2023-02-07 |
2024-08-15 |
Captor Therapeutics S.A. |
Gspt1 degrader compounds
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
TW202530189A
(zh)
|
2023-09-29 |
2025-08-01 |
日商第一三共股份有限公司 |
3-苯基丙基胺衍生物
|
|
AU2024392985A1
(en)
|
2023-12-08 |
2026-06-04 |
Arvinas Operations, Inc. |
Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
|
|
AU2023477303A1
(en)
|
2023-12-22 |
2026-06-04 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target protein kinase c
|